Latest / CME Outfitters Medical Education / Rethinking Suppression: GnRH Antagonists and Contemporary Endometriosis Management
Transcript
- 0:00SPEAKER_00: Hello and welcome.
- 0:02SPEAKER_00: On behalf of CME Outfitters, thank you for joining this CMEO SNAC titled Rethinking Suppression: GNRH Antagonists and Contemporary Endometriosis Management.
- 0:15SPEAKER_00: This program is supported by an educational grant from Sumitomo Pharma America.
- 0:21SPEAKER_00: Today's activities may include discussions of products or devices that are not currently labeled for use by the FDA.
- 0:29SPEAKER_00: As faculty, we've been informed of our responsibility to disclose to you if we discuss any off-label or investigational uses of products or devices.
- 0:40SPEAKER_00: I'm Dr.
- 0:40SPEAKER_00: Hugh Taylor, and I'm delighted to be joined today by my colleague, Dr.
- 0:44SPEAKER_00: Anna Shanahan.
- 0:46SPEAKER_01: Thanks so much, Hugh.
- 0:47SPEAKER_01: I'm Dr.
- 0:48SPEAKER_01: Anna Shanahan, and I'm excited to be here to discuss how we can bring more intentional patient-centered care to women with endometriosis associated pain.
- 0:58SPEAKER_00: Let's start with our first learning objective for today's program: apply evidence-based use of GNRH antagonists for non-surgical management of endometriosis associated pain, including appropriate patient selection, dosing strategies, monitoring, and treatment positioning.
- 1:21SPEAKER_00: Before we get into escalation and the role of GNRH antagonists, let's briefly level set on diagnosis and where we start with first-line therapy.
- 1:32SPEAKER_00: So endometriosis today should be diagnosed clinically.
- 1:37SPEAKER_00: Endometriosis for too long has been delayed in our ability to diagnose this up to six to ten years from symptom onset.
- 1:48SPEAKER_00: The clinical presentation, though, is quite clear, and the American College of OBGYN has recently suggested that clinical diagnosis and empiric treatment is appropriate.
- 1:59SPEAKER_00: Endometriosis typically presents initially with dysmenorrhea that is severe and progressive.
- 2:07SPEAKER_00: That's one of the key points to understanding endometriosis.
- 2:12SPEAKER_00: Menstrual cramps can be considered normal, but they shouldn't get worse over time.
- 2:18SPEAKER_00: When they're either severe or they're progressively getting worse, think endometriosis.
- 2:23SPEAKER_00: Endometriosis may also present with non-menstrual pelvic pain.
- 2:28SPEAKER_00: Dysperunia is common or painful intercourse.
- 2:31SPEAKER_00: Dystcheesia or pain with bowel movements sometimes occurs, and dysuria or painful urination is very common.
- 2:39SPEAKER_00: Infertility is also one of the classic characteristics of endometriosis that may occur with or without pain.
- 2:48SPEAKER_00: So, what is your diagnostic approach?
- 2:50SPEAKER_00: I think we have to have a very high level of suspicion based on symptoms.
- 2:56SPEAKER_00: We have to listen to our patients.
- 2:58SPEAKER_00: We perform a pelvic exam, not because you can always detect endometriosis on a pelvic exam, but to rule out potential other etiologies of pain.
- 3:22SPEAKER_00: But it's important to remember surgical confirmation is no longer required before beginning therapy.
- 3:48SPEAKER_00: Any other pain a human being has, we would consider abnormal and want to diagnose and treat it.
- 3:56SPEAKER_00: This is too easy to dismiss as something that is normal.
- 3:59SPEAKER_00: And pain is so subjective.
- 4:01SPEAKER_00: How do you know if your pain is worse than someone else's?
- 4:04SPEAKER_00: So too often, dysmenorrhea is dismissed by friends, family, caregivers.
- 4:12SPEAKER_00: That results in multiple visits to uh physicians' offices, the pain not getting recognized, persistent symptoms, and diagnosis is quite delayed.
- 4:23SPEAKER_00: So very simple.
- 4:24SPEAKER_00: If somebody has progressive severe dysmenorrhea, make that diagnosis of endometriosis and begin treatment.
- 4:33SPEAKER_01: Conventional first-line management for endometriosis associated pain centers on three categories.
- 4:39SPEAKER_01: We have NSAIDs, uh, combined hormonal contraceptives, so uh hormonal contraceptives with both estrogens and progestin, and also progestin-only options.
- 4:48SPEAKER_01: So the key takeaway is that persistent symptoms, despite adequate first-line suppression, should prompt reassessment and consideration of escalation strategies rather than repeatedly cycling through similar approaches, such as trying different combined hormonal contraceptive methods over and over instead of trying something different.
- 5:09SPEAKER_00: So there's a huge burden of untreated endometriosis associated pain.
- 5:15SPEAKER_00: Why is this important?
- 5:16SPEAKER_00: Why does it matter?
- 5:17SPEAKER_00: It's because there are 190 million women affected worldwide.
- 5:21SPEAKER_00: That's 10% of the reproductive age population.
- 5:25SPEAKER_00: Because of this huge delay, Wiffman are often suffering before they get a diagnosis and treatment for years.
- 5:34SPEAKER_00: And even first-line therapies often fail.
- 5:38SPEAKER_00: About half the time when you start an oral contraceptive, it is not appropriate, it either doesn't work or has significant side effects.
- 5:46SPEAKER_00: And when someone is suffering with pain from endometriosis, not only does it affect their personal life, their relationships, but there's also a much higher rate of absenteeism from work or lack of productivity at work.
- 5:59SPEAKER_00: So we need to stop delaying diagnosis and uh move on to make that diagnosis clinically early on in the course of the disease, where we can be more effective at treating it.
- 6:12SPEAKER_00: And I think we need to recognize when the first-line therapy is ineffective.
- 6:18SPEAKER_00: Uh, note that we need to reassess uh fairly frequently and move on to great secondline options that are now available, uh, largely the GRH antagonists, which are currently underutilized, despite guidelines that support their use of secondline therapy and robust phase three clinical trial data.
- 6:44SPEAKER_01: And this is what the pattern looks like in the real world.
- 6:47SPEAKER_01: So, like we talked about that first-line suppression with the NSADs, the combined hormonal contraceptives or the progestins, which often get cycled over and over despite those persistent symptoms and the repeated switching that occurs.
- 7:01SPEAKER_01: And so that uh just like you mentioned, um, results in delayed escalation.
- 7:06SPEAKER_01: So NSADs and CHE still remain the dominant prescribing choices, and the consequence is prolonged ineffective therapy and that repeated cycling and premature surgical referral as well.
- 7:18SPEAKER_01: So the optimized pathway is interrupting that cycle at the second step.
- 7:24SPEAKER_01: The opportunity to intervene is at that persistent symptom step, not after cycling through three to four combined hormonal contraceptive options.
- 7:32SPEAKER_00: So, what are some of the barriers to this optimized management program that we've just discussed?
- 7:38SPEAKER_00: Well, sometimes it's the clinicians that aren't familiar with some of these newer agents, and hopefully we'll learn more about that today so that will not be an issue for anybody listening to this program.
- 7:49SPEAKER_00: Uh, we also sometimes delay or uncertain about when to escalate.
- 7:54SPEAKER_00: We'll talk about the appropriate timing of escalation to a second-line therapy, and we'll also talk about any concerns about bone health and the use of adback therapy to make sure we keep bones safe.
- 8:07SPEAKER_00: Sometimes there are system-level problems that include limited specialists who are experts in endometriosis.
- 8:14SPEAKER_00: We all know we have limited time to see patients and how pressured those visits can be that we don't have time to discuss everything we'd like to in a single visit.
- 8:23SPEAKER_00: And inconsistent reassessment workflows.
- 8:26SPEAKER_00: We don't prescribe an oral contraceptive and just say come back in a year.
- 8:31SPEAKER_00: This is not the same as an annual exam.
- 8:33SPEAKER_00: We need closer follow-up in patients with endometriosis, but sometimes that's hard to do uh with standardized reassessment uh cycles in some practices.
- 8:44SPEAKER_00: Also, the patients get frustrated.
- 8:46SPEAKER_00: Their pain has been normalized, uh, they dismissed, they may even stop talking about it, they may have had negative experiences with their friends, family, and physicians who haven't recognized the severity of their pain or who haven't moved them on to a more effective therapy in an appropriate timeline.
- 9:05SPEAKER_00: And patients may also have concerns about long-term medication use that we can discuss throughout today's presentation.
- 9:13SPEAKER_00: So let's discuss the FDA-approved GNRH antagonists that we use for non-surgical management of endometriosis.
- 9:23SPEAKER_00: These have largely replaced the old-fashioned GNRH agonists.
- 9:29SPEAKER_00: These were injectable drugs, once a month depot injection that initially stimulate the GNRH receptor and cause a flare effect, a stimulation that leads to increased FSH and LH production, an increase in estradiol, and actually some exacerbation of the disease for a week or two before they're effective.
- 9:54SPEAKER_00: So uh these have a delay, uh, they're injectable and irreversible, or at least uh it takes a long time for this depot formulation to be reversed.
- 10:06SPEAKER_00: The GNRH antagonists are the contemporary drugs that have largely replaced the old-fashioned GNRH agonists.
- 10:14SPEAKER_00: These are oral medications that work very rapidly, they directly block the receptor and immediately decrease FSH and LH.
- 10:24SPEAKER_00: So you get a very rapid decrease in estradiol, they start to work almost immediately.
- 10:30SPEAKER_00: So, how do we position them?
- 10:32SPEAKER_00: Well, uh, first line therapy will continue to be non-steroidals and hormonal contraceptive agents, but we need to think about the inadequate response that we frequently see.
- 10:46SPEAKER_00: These oral contraceptives fail about half the time, and we need to be ready to move to a GNRH antagonist and with ADBAC therapy if needed.
- 10:56SPEAKER_00: We need to think about using them earlier in the course than is typically done if an estrogen progestin combination is either contraindicated because of some contraindication to estrogen use, or if we really need to control symptoms rapidly.
- 11:15SPEAKER_00: So if someone fails, oral contraceptives, if someone has a contraindication of use of estrogen, or if somebody has very severe pain that you want to control quickly without this trial and error phase, think about using GNRH antagonists early and perhaps as first-line therapy.
- 11:36SPEAKER_00: There are two FDA-approved uh GNRH antagonists on the market today.
- 11:42SPEAKER_00: One, the first approved, was Eligolix.
- 11:45SPEAKER_00: It comes in two different doses: 150 milligrams once a day that gives you partial suppression, or 200 milligrams twice daily that gives full suppression.
- 12:00SPEAKER_00: These were not studied and do not come with ADBAC hormone therapy included.
- 12:06SPEAKER_00: For 150, you often don't need it, but at 200 often there are vasomotor symptoms or side effects.
- 12:12SPEAKER_00: Uh, and ADBAC therapy can be used off-label.
- 12:16SPEAKER_00: This is not FDA approved, but can be used off-label uh to support someone using a higher dose.
- 12:23SPEAKER_00: The newer uh GNRH antagonist on the market is religolix.
- 12:29SPEAKER_00: Uh, this is also approved for moderate to severe pain due to endometriosis.
- 12:34SPEAKER_00: Religolix uh is a once-a-day regimen that includes built-in adback therapy, one milligram of estradiol with one half milligram of norethindrone.
- 12:47SPEAKER_00: So the ADBAC's included, and this is extended the duration uh for up to two years because of this hormone ADBAC therapy.
- 12:56SPEAKER_00: One of the problems with the use of oral contraceptives is progesterone resistance.
- 13:02SPEAKER_00: We now understand the molecular basis for why first-line oral contraceptive hormone therapy fails.
- 13:10SPEAKER_00: In normal endometrium and mild endometriosis, the progesterone receptor is expressed, and progesterone stops the estrogen-deliver-driven proliferation and inflammation.
- 13:26SPEAKER_00: In endometriosis, and markedly more so in some severe treatment-resistant endometriosis, the progesterone receptor is dramatically reduced or even absent.
- 13:39SPEAKER_00: The endometriosis will not respond to progestins in an oral contraceptive.
- 13:45SPEAKER_00: Uh, that leads to persistent estrogen signaling, persistent proliferation, persistent inflammation.
- 13:54SPEAKER_00: So when we have this progestin-resistant endometriosis, uh, the pain won't be resolved by giving a progestin.
- 14:03SPEAKER_00: There's no progestin receptor, and switching from one oral contraceptive to another just doesn't make sense.
- 14:13SPEAKER_00: If the progestin receptor isn't there, that endometriosis won't respond to any progestin.
- 14:20SPEAKER_00: So one pill formulation versus another does not make sense.
- 14:24SPEAKER_00: If someone isn't responding to an oral contraceptive, you should always go to second-line therapy.
- 14:31SPEAKER_00: And today, that is a GNRH antagonist.
- 14:34SPEAKER_00: It of course does not work through the progestin receptor.
- 14:38SPEAKER_00: It works upstream, suppresses estrogen production, and will treat endometriosis, even progestin-resistant endometriosis.
- 14:48SPEAKER_00: There is um great evidence from multiple phase three trials uh that support use of eligolics and religolics for endometriosis.
- 15:00SPEAKER_00: These are the Illaris one in two trials for elegolics and the spirit one in two trials for religolics combination therapy.
- 15:10SPEAKER_00: Again, these are large phase three, double-blinded, randomized placebo controlled trials.
- 15:16SPEAKER_00: And for elegolics, the 150 milligram once-a-day dosing, the low dose, gives you 46% responder rate uh for a dysmenorrhea.
- 15:28SPEAKER_00: Uh, it's best for, I think, the milder forms of endometriosis pain.
- 15:35SPEAKER_00: In this study, uh patients with moderate to severe pain were included.
- 15:40SPEAKER_00: Um the higher dose, even in moderate to severe pain, gave you a 76% responder rate.
- 15:50SPEAKER_00: So very good responder rate for those with moderate to severe disease, a little bit lower for the low dose allegolics, but I don't use that in those with the severe disease.
- 16:00SPEAKER_00: I tend to use that for those with only milder forms of pain.
- 16:04SPEAKER_00: Uh, there's also a significant improvement in non-menstrual pelvic pain compared to uh placebo.
- 16:12SPEAKER_00: In the Alaris trials using allegolics, there was a dose-dependent hypoestrogenic effect.
- 16:18SPEAKER_00: There were some vasomotor symptoms and bone mineral uh density reduction.
- 16:23SPEAKER_00: At 150 milligrams, that was not very severe, but at 200 milligrams twice a day, there were a considerable number of hot flushes.
- 16:33SPEAKER_00: But again, off-label, not included in the trial, we can use hormone replacement therapy as adback to eliminate the vasomotor symptoms and prevent the loss of bone mineral density.
- 16:48SPEAKER_00: In the spirit trials, again, this is religolic combination therapy that includes ADBAC therapy in a single once daily tablet, there was a 75% responder rate for dysmenorrhea.
- 17:01SPEAKER_00: So it works very well.
- 17:02SPEAKER_00: And again, these are all patients with moderate to severe pain, many of whom in both trials had failed oral contraceptives.
- 17:11SPEAKER_00: So even in those patients who need second-line therapy, very good response rate.
- 17:17SPEAKER_00: And importantly, in these trials, in order to be considered a responder, you had to not only have a statistically significant difference in pain, but a clinically meaningful difference and not have an increased use in narcotics.
- 17:33SPEAKER_00: Rilla Golix also showed a great uh response in non-menstrual pelvic pain and continued to show improvement throughout a year-long trial.
- 17:45SPEAKER_00: So, this fixed dose combination therapy that includes the ADBAC, estradyl, and northendrone prevents the vasomotor symptoms, uh, prevents loss of bone, um, and makes a very simple once-daily, all-inclusive pill with everything in it, including the ADBAC, once daily pill that we can use very easily, very patient-friendly regimen.
- 18:10SPEAKER_00: So, how do we select uh patients for evaluating whether GNRH antagonist therapy is the right choice?
- 18:17SPEAKER_00: Well, we look at their prior treatment response.
- 18:21SPEAKER_00: If they have had inadequate pain control after three months on first-line suppression, uh, they should definitely move on to a second-line therapy.
- 18:31SPEAKER_00: If they've failed on a progestin in the past, uh the slide says one to two combined oral contraceptives, I say one, again, as we talked about, with the progestin receptor not being there, they're not going to respond to any progestin.
- 18:47SPEAKER_00: So if they failed one oral contraceptive or progestin formulation, move to second-line therapy.
- 18:55SPEAKER_00: Or if the patient is severely disabled by their disease, they're missing work, their quality of life is severely impaired, think about using a GNRH antagonist as first-line therapy.
- 19:09SPEAKER_00: What's the symptom profile that we're looking at?
- 19:11SPEAKER_00: Well, the predominant pain type, whether it's dysmenorrhea, non-menstrual pelvic pain, dysperunia, that's one of the hardest to treat, or a combination of the above.
- 19:21SPEAKER_00: The more severe the pain, the more likely they are to need a second-line therapy, especially dysperunia is a key symptom that is most refractory to treatment.
- 19:32SPEAKER_00: Look at the severity and functional impact on work, relationships, their daily activities.
- 19:37SPEAKER_00: Again, the more severely affected they are by the disease, the more likely they will need the GNRH antagonist.
- 19:46SPEAKER_00: Also, think about using a GNRH antagonist earlier if they have suspected or confirmed deep infiltrating endometriosis.
- 19:54SPEAKER_00: That's often harder to treat, more inflammatory causes more pain, or potentially those with large endometriomas.
- 20:02SPEAKER_00: We also need to think about safety and tolerability issues.
- 20:06SPEAKER_00: Um, vasomotor symptoms are the most common side effect of these medications.
- 20:11SPEAKER_00: We can either use add back and give that separately, prescribed as a separate um uh um pill or two pills if we're using an estrogen and a progestin.
- 20:23SPEAKER_00: Um, again, this is off-label, but should be used for somebody who has vasomotor symptoms, or it's included in the religolics combination therapy that has the generate gentagonist, estrogen, progestin, all in one.
- 20:36SPEAKER_00: Think about monitoring bone mineral density, especially if there are risk factors.
- 20:42SPEAKER_00: Um, if you're using beyond the FDA recommendations, which are six months for the Legolics 200, uh, you should definitely use um a uh method to monitor bone mineral density, a DAXA scan.
- 20:59SPEAKER_00: Um, and for those who might be at risk uh for liver disease, think about monitoring liver function tests.
- 21:07SPEAKER_00: Uh, our patient goals also need to be taken into consideration and their preferences.
- 21:13SPEAKER_00: Fertility goals are important.
- 21:15SPEAKER_00: Uh allegolics is not a contraceptive, and we need to address contraceptive um uh coverage separately.
- 21:24SPEAKER_00: Uh, we need to think about the root preference.
- 21:28SPEAKER_00: The old-fashioned injectable GNRH agonists, I can tell you, are not popular.
- 21:33SPEAKER_00: Everyone would rather have an oral medication.
- 21:36SPEAKER_00: Um, and the once daily combination therapy makes it quite easy.
- 21:42SPEAKER_00: Um, also anticipate some of these side effects, phasomotor symptoms.
- 21:47SPEAKER_00: We can treat those.
- 21:49SPEAKER_00: Bleeding expectations, especially when we first are on a new hormone regimen.
- 21:54SPEAKER_00: Some spotting is not uncommon uh early on in the course of.
- 22:00SPEAKER_00: This medication, it disappears, and amenorrhea is most common on the high dose of algolics or the religolics.
- 22:09SPEAKER_00: Uh, cycles usually persist on the lower dose of Legolics.
- 22:13SPEAKER_00: But I tell them to anticipate amenorrhea, but with some irregular bleeding in the first uh uh few weeks of use.
- 22:24SPEAKER_00: So let's present a case and uh question for you.
- 22:27SPEAKER_00: Sophia is a 32-year-old woman with confirmed endometriosis and moderate to severe dysmenorrhea, and additionally has non-menstrual pelvic pain.
- 22:40SPEAKER_00: She has been on a combined oral contraceptive for five months with only minimal improvement.
- 22:47SPEAKER_00: She is not currently trying to conceive, but plans to start trying in approximately six months.
- 22:53SPEAKER_00: She is worried that starting a new medication now may interfere with her ability to get pregnant.
- 23:00SPEAKER_00: She has no contraindications to estrogen use.
- 23:03SPEAKER_00: What would be your most likely next step?
- 23:09SPEAKER_00: Well, A, continue the current combined oral contraceptive for three more months given her near-term pregnancy plans.
- 23:18SPEAKER_00: B initiate a GNRH antagonist-based regimen now and provide further counseling on contraceptive needs, treatment goals, and discontinuation timing when she's ready to conceive.
- 23:34SPEAKER_00: C, discontinue all hormone therapy and refer to reproductive endocrinology before initiating anything, though.
- 23:41SPEAKER_00: D.
- 23:42SPEAKER_00: Switch to a progeston only option given her pregnancy plans.
- 23:46SPEAKER_00: Or E, I don't know.
- 23:48SPEAKER_00: If you really don't know, it's an honest answer.
- 24:09SPEAKER_00: I think the best answer here is uh B, she's not getting relief, minimal improvement on the combined oral contraceptive.
- 24:18SPEAKER_00: She needs a second-line therapy.
- 24:21SPEAKER_00: Uh five months is more than an adequate trial.
- 24:25SPEAKER_00: Again, I think six to eight weeks is an adequate trial of a combined oral contraceptive.
- 24:32SPEAKER_00: If she's not responding, switch to the GNRH antagonist regimen.
- 24:37SPEAKER_00: Um uh she can easily stop that when she wants to conceive.
- 24:43SPEAKER_00: Six months is not a long time.
- 24:45SPEAKER_00: And the beauty about the GNRH antagonists is that they reverse very rapidly.
- 24:52SPEAKER_00: Once you stop them, within 24-48 hours, uh the ovaries are reactivated and fertility is rapidly restored.
- 25:01SPEAKER_00: So it's actually the perfect agent to use in somebody planning to conceive.
- 25:06SPEAKER_00: We can give her the six months of relief from her pain.
- 25:11SPEAKER_00: We can quiet down that endometriosis and then rapidly restore fertility when it's needed.
- 25:18SPEAKER_00: This is a perfect patient who would benefit from escalation to a GNRH antagonist.
- 25:26SPEAKER_01: Let's transition to our second learning objective, which is individualizing non-surgical endometriosis treatment by integrating patient goals, key clinical characteristics, and current evidence into a tailored medical plan.
- 25:40SPEAKER_01: So this is where we move from which drug to which drug for this specific patient, and where shared decision making becomes essential.
- 25:48SPEAKER_01: So endometriosis treatment is preference sensitive.
- 25:53SPEAKER_01: Individual patient values include fertility goals, like we mentioned, tolerance for bleeding changes, willingness to accept those hypoestrogenic effects, root and frequency preferences, the comorbidities and contraindications, access to follow-up, and health literacy.
- 26:11SPEAKER_01: So there's no single bust regimen.
- 26:13SPEAKER_01: When we skip structured shared decision making, the consequences are predictable.
- 26:18SPEAKER_01: You know, early discontinuation, uh especially when unmet expectations happen, like bleeding, timing, or side effects, then those can cause therapy to be stopped before the benefit is realized.
- 26:30SPEAKER_01: And suboptimal adherence among patients who feel unheard or misunderstood, persistent symptom burden, um, and missed opportunity when we default to a familiar regimen rather than the optimal one for that specific patient.
- 26:47SPEAKER_01: So here's a practical three-step framework you can use in routine visits.
- 26:52SPEAKER_01: So the ESHRE guideline, and the ESHRE is the European Society of Human Reproduction and Endro uh Embryology.
- 27:01SPEAKER_01: Pardon me.
- 27:02SPEAKER_01: The ESHRE guideline specifically recommends a shared decision-making approach and that clinicians take individual preferences, side effects, individual efficacy, costs, and availability into consideration when choosing hormone treatments for endometriosis associated pain.
- 27:19SPEAKER_01: So, first you can see that the first step here is illicit.
- 27:23SPEAKER_01: And so a way I like to think about this is what are the patient's priorities?
- 27:28SPEAKER_01: Like you mentioned, is it going to be fertility?
- 27:30SPEAKER_01: Is it the concern about the bleeding?
- 27:32SPEAKER_01: And so eliciting what they're concerned about.
- 27:35SPEAKER_01: And that can include the quality of life, that can include contraceptive means as well.
- 27:40SPEAKER_01: Second step being inform and not just defaulting to what we may usually do or what we've been doing.
- 27:48SPEAKER_01: We are explaining treatment options to our patients, communicating trade-offs, setting realistic expectations again, so that way there's no early discontinuation and addressing common misconceptions as well.
- 28:00SPEAKER_01: And then collaborate, that shared decision making.
- 28:03SPEAKER_01: I love this for patients because this looks uh different and maybe functional or reproductive, but aligning the treatment choice again to the patient's priorities and establishing a follow-up plan.
- 28:16SPEAKER_01: I think timeline can be very important for our patients.
- 28:19SPEAKER_01: So again, setting those expectations about how long it may take before they see the benefit, and then offering teach back as well, which is always helpful to make sure that our parent that our patients are understanding.
- 28:31SPEAKER_00: So let's compare some of the trade-offs among the different medical options that are available to us today.
- 28:37SPEAKER_00: First line therapy is typically, again, as we've discussed, a combined oral contraceptive that can be either given in a cyclic fashion or continuous fashion to eliminate menses.
- 28:48SPEAKER_00: If dysmenorrhea is uh the issue, eliminating menses may be helpful.
- 28:53SPEAKER_00: Or really any progestin uh works similarly.
- 28:58SPEAKER_00: These do reduce dysmenorrhea, they have a more variable effect on non-menstrual pelvic pain and some of the more severe pain, especially the dystesia dysperonia.
- 29:10SPEAKER_00: We expect that they should work within four to eight weeks.
- 29:13SPEAKER_00: So remember, there's about a 50% failure rate with oral contraceptives.
- 29:19SPEAKER_00: Check back with them in six to eight weeks.
- 29:21SPEAKER_00: If it's not working, time to escalate.
- 29:24SPEAKER_00: One of the key points is breakthrough bleeding is common initially on a combined oral contraceptive.
- 29:31SPEAKER_00: And again, a continuous roove may improve efficacy.
- 29:35SPEAKER_00: If we have dysmenorrhea, why not eliminate menses?
- 29:38SPEAKER_00: Um, of course, these shouldn't be used if somebody has a contraindication uh to estrogen, but they also do provide a contraceptive benefit if that's desired.
- 29:51SPEAKER_00: Second uh therapy that we can use is a levonomergesterol-containing intrauterine system.
- 29:58SPEAKER_00: This works well for reducing dysmenorrhea, reduces menstrual flow, it may cause amenorrhea completely, but very limited effect outside the uterus.
- 30:09SPEAKER_00: This is not a great treatment for the non-menstrual pelvic pain or some of the other pains we talked about earlier.
- 30:16SPEAKER_00: Works best for dysmenorrhea when endometriosis-related dysmenorrhea is the primary complaint.
- 30:22SPEAKER_00: Think about using uh the liverone or dresterol interuterine system.
- 30:27SPEAKER_00: This may take a little longer to have an effect, so be a little more patient, give this a little more leeway, and expect some spotting for the first few months.
- 30:37SPEAKER_00: Amenorrhea is common and actually desirable in some barindometriosis patients in the long term.
- 30:44SPEAKER_00: Uh, this is best for patients who want contraceptive and who I are open to the idea of an intrauterine option.
- 30:55SPEAKER_00: They don't mind that placement of the intrauterine system, and don't need systemic hormone treatment where the pain is really isolated to dysmenorrhea.
- 31:09SPEAKER_00: As we discussed, isn't as effective as the high dose, but um reduces dysmenorrhea and some non-menstrual pelvic pain.
- 31:19SPEAKER_00: Uh, use the higher dose if they have more severe pain.
- 31:23SPEAKER_00: Uh, but the low dose um has some hot flushes, but they're uncommon and mild.
- 31:31SPEAKER_00: Um, if we go to the 200 milligrams twice a day, then that is something you should think about adding adbac therapy.
- 31:39SPEAKER_00: The vasomotor symptoms become more common, and bone mineral density is something you want to also take into account.
- 31:47SPEAKER_00: Uh, again, using that ADBAC can minimize that bone loss.
- 31:52SPEAKER_00: Uh, this drug, though, uh, either at the low dose or even better at the higher dose, works well for those who failed first-line therapy.
- 32:02SPEAKER_00: The GNRH antagonists should be go-to drugs for those who failed that first-line therapy with a combined oral contraceptive.
- 32:11SPEAKER_00: The other option we have available today is the religolics combination therapy.
- 32:15SPEAKER_00: That's religolics with low-dose estradiol and northindrone.
- 32:20SPEAKER_00: Uh, this reduces dysmenorrhea and that non-menstrual pelvic pain, sustained efficacy after a year or more.
- 32:27SPEAKER_00: Uh, again, the response time is relatively quick, four to eight weeks.
- 32:32SPEAKER_00: And because of that built-in ad-back hormone therapy, there are very few vasomotor symptoms and a relatively neutral effect on bone mineral density.
- 32:45SPEAKER_00: So, again, we have two GNRH antagonists, the elegolics or the religolics, uh, that one should escalate to rapidly.
- 32:54SPEAKER_00: Again, after four to eight weeks, if there's no response on a combined oral contraceptive or significant side effects, move to one of these GNRH antagonists rather quickly.
- 33:09SPEAKER_01: Personalization means accounting for the patient's whole clinical picture.
- 33:12SPEAKER_01: So let's walk through four of the most common contexts that change our decisions.
- 33:18SPEAKER_01: Uh, first being migraine with aura or VTE risk factors.
- 33:23SPEAKER_01: And for someone like this, uh, you're looking at possibly avoiding estrogen-containing regimens and using progestin-on options.
- 33:31SPEAKER_01: Religolics combination does contain that E2 NETA, so evaluate that risk benefit.
- 33:37SPEAKER_01: And again, counseling on those phaser motor effects.
- 33:41SPEAKER_01: Fertility goals, that's certainly important, not contraceptive, um, addressing contraception separately.
- 33:49SPEAKER_01: And certainly, as you mentioned, we can do a GNRH antagonist now and discontinue before the patient is planning on conception.
- 33:59SPEAKER_01: Mood disorders and mental health also important.
- 34:03SPEAKER_01: An important point is hypoestrogenic states can actually worsen mood.
- 34:06SPEAKER_01: So making sure that there's realistic expectations surrounding that.
- 34:10SPEAKER_01: And then rural or underserved settings where follow-up might be difficult, simplicity of regimens might be important as well.
- 34:17SPEAKER_01: And just to mention that referral to reproductive endocrinology or minimally invasive gynecologic surgery is appropriate for refractory symptoms despite adequate medical management, or suspected deep infiltrating disease, or fertility-related surgical evaluation.
- 34:35SPEAKER_01: That's just not our main focus for today, but absolutely that can be an appropriate step.
- 34:40SPEAKER_00: One of the biggest challenges in uh diagnosing endometriosis is that there are many overlapping and co-occurring conditions in endometriosis.
- 34:51SPEAKER_00: Bowel pain can uh be common uh in other diseases, but it's common in endometriosis, bladder pain, pelvic floor dysfunction.
- 35:02SPEAKER_00: It's important to distinguish these.
- 35:04SPEAKER_00: If somebody has symptoms that include destchesia, bloating, altered bowel habits, endometriosis when it's severe, almost always causes this, especially if those symptoms are cyclic.
- 35:19SPEAKER_00: If it's an underlying bowel disease, uh they don't just have that disease during the time of menstruation or around the time of the period.
- 35:28SPEAKER_00: So, especially if these symptoms are predominantly cyclic, um, think that it's endometriosis first.
- 35:35SPEAKER_00: It's Occam's razor.
- 35:37SPEAKER_00: There's usually one underlying diagnosis rather than have multiple coexisting diseases.
- 35:43SPEAKER_00: This has been one of the biggest challenges in diagnosing endometriosis, is all of these other symptoms will cause us to go on these diagnostic dilemmas.
- 35:54SPEAKER_00: And patients are often referred out to multiple different specialists before focusing on the endometriosis.
- 36:00SPEAKER_00: Recognize that the bowel symptoms, for example, are very commonly caused by endometriosis.
- 36:08SPEAKER_00: Um, think about treating the endometriosis first, and then when the bowel symptoms are still there despite adequate treatment of endometriosis, then think about uh a bowel um diagnosis or referral to gastroenterology.
- 36:24SPEAKER_00: But I can't tell you the number of patients I have that have had uh menstrual-related bowel symptoms, were seen first by a gastroenterologist, had a colonoscopy that was negative, and eventually found their way to me.
- 36:37SPEAKER_00: Start by treating the endometriosis.
- 36:40SPEAKER_00: It's the same with bladder pain, um, pelvic pain, urinary urgency, dysuria, especially when they're cycle-related, when they occur predominantly around the time of menses, think endometriosis first, um, and only think about referring to a urologist uh for a potential diagnosis of interstysal cystitis if the bladder symptoms persist even after treating the endometriosis.
- 37:09SPEAKER_00: Again, a pelvic floor dysfunction can uh be seen in endometriosis.
- 37:18SPEAKER_00: Um and often these symptoms develop secondary to the chronic pain.
- 37:24SPEAKER_00: Pelvic floor therapy is a great adjunctive therapy, but is not the primary therapy for treating endometriosis.
- 37:32SPEAKER_00: Treat the endometriosis first and then address these other problems if they still remain.
- 37:38SPEAKER_00: You'll find most of the time these other symptoms go away when you've adequately managed their endometriosis.
- 37:45SPEAKER_00: So recognizing that there are multiple overlapping symptoms, uh, but think endometriosis first, suppress the endometriosis, and address these uh other symptoms uh if they are not responsive once the endometriosis is controlled.
- 38:06SPEAKER_01: Let's apply the shared decision-making framework to another case.
- 38:10SPEAKER_01: So Priya is a 34-year-old woman with confirmed endometriosis and persistent dysmenorrhea and NMPP.
- 38:18SPEAKER_01: She works two jobs in a rural area and cannot return frequently for follow-up.
- 38:22SPEAKER_01: She is concerned about irregular bleeding, has no estrogen contraindications, and is not currently trying to conceive, but wants the option within two years.
- 38:31SPEAKER_01: What is your next step?
- 38:33SPEAKER_01: A.
- 38:34SPEAKER_01: Initiate northendrone acetate and schedule follow-up in three months, address bleeding if it occurs.
- 38:41SPEAKER_01: B.
- 38:41SPEAKER_01: Discuss GNRH antagonist options, including differences in ADBAC, dosing, safety, monitoring duration limits, contraception needs, and access, and select therapy through shared decision making and plan for follow-up at 8 to 12 weeks.
- 38:56SPEAKER_01: Refer to a specialist before initiating any new therapies given the complexity of her situation, or D.
- 39:02SPEAKER_01: Offer Alagalux 200 milligrams BID for maximum efficacy and schedule a bone density scan at six months, or E, I don't know.
- 39:11SPEAKER_01: Always an appropriate option, also.
- 39:39SPEAKER_01: And so B would be the most appropriate answer so that again, you can do that shared decision-making model and talk about what are the patient's priorities, what is she most concerned about, what is the timeline, what are the expectations?
- 39:53SPEAKER_01: Certainly, some of these other options could potentially be what you settle on.
- 39:57SPEAKER_01: Perhaps she would like eventually to do A or D, but we shouldn't just assume that she wants one particular therapy without further discussion.
- 40:06SPEAKER_01: And her bleeding concerns need to be addressed up front.
- 40:09SPEAKER_01: And her fertility timeline matters, even though she's not currently trying.
- 40:12SPEAKER_01: So this case highlights the importance of bringing access, bleeding concerns, daily functioning, and fertility timeline into the shared decision-making conversation.
- 40:23SPEAKER_00: How do we implement these guidelines in a really time-pressured practice?
- 40:29SPEAKER_00: How can we improve our workflow?
- 40:31SPEAKER_00: Well, I think one thing I found very helpful is to have a pre-visit symptom questionnaire that looks at pelvic pain, quality of life, bleeding.
- 40:41SPEAKER_00: Uh the patients often will tell us that they feel unheard because there just isn't time in a busy practice to go over all of the symptoms.
- 40:51SPEAKER_00: But with a symptom diary, you can really highlight the most important symptoms to them, have them summarized in a nice, clear, distinct fashion, and address them and let that patient feel heard.
- 41:04SPEAKER_00: The other thing we need to do is make sure that we get patients back for reassessment.
- 41:08SPEAKER_00: This is not the standard prescribe your oral contraceptive and see you in a year.
- 41:14SPEAKER_00: We need to have them come back in six weeks, 12 weeks, somewhere in that time frame, make sure that that's appropriate.
- 41:24SPEAKER_00: That we can monitor them uh within weeks of prescribing an oral contraceptive, escalate them if uh the oral contraceptive fails, which again is going to happen about 50% of the time.
- 41:39SPEAKER_00: We also can let them know what potential triggers uh might cause escalation.
- 41:46SPEAKER_00: If their pain isn't improved by eight weeks, they should know that we have something else to offer.
- 41:52SPEAKER_00: Again, patients feel dismissed and unheard.
- 41:55SPEAKER_00: We need to let our patients know that the first-line therapy isn't the end point.
- 42:00SPEAKER_00: We are there for them.
- 42:01SPEAKER_00: We will provide them with second-line therapy uh if needed to alleviate their pain.
- 42:06SPEAKER_00: And for patients with limited access, telehealth uh is often a very good app option.
- 42:13SPEAKER_00: You've already done your exam.
- 42:14SPEAKER_00: You really just need to find out whether your treatment's working.
- 42:17SPEAKER_00: This could easily be done over telehealth and symptom diarrhea or app also is very helpful in tracking those symptoms while they're on that first-line therapy or as they are beginning a course of their second line therapy again, a GNRH antagonist.
- 42:36SPEAKER_01: The other half of implementation is how we communicate in the room with the patient.
- 42:40SPEAKER_01: In short visits, plain language and teachback matter, validating the patient's experience, asking one priority question, and closing with a concrete follow-up plan.
- 42:50SPEAKER_01: Certainly we can supplement this with providing written materials.
- 42:54SPEAKER_01: As you said, acknowledging that the pain is real and has been undertreated.
- 42:58SPEAKER_01: Validation of what the patient is experiencing is extremely important.
- 43:02SPEAKER_01: And again, addressing which priorities are most important for our patient and using that shared decision-making model.
- 43:08SPEAKER_01: It's okay to not present them with a full table of 10 plus options.
- 43:12SPEAKER_01: You can narrow down to two potential options concretely with brief trade-offs and avoid information overload.
- 43:20SPEAKER_01: And certainly closing with does this plan make sense to you can be important or more open-endedly.
- 43:25SPEAKER_01: What questions do you have?
- 43:27SPEAKER_00: So let's talk about what we call our SMART goals, specific, measurable, attainable, relevant, and timely goals that we can use to put this information into action.
- 43:38SPEAKER_00: Consider the following goals, then set a time frame that fits with your work environment and that will really provide a reasonable improvement target for your patients that aligns with their desires and needs.
- 43:53SPEAKER_00: Importantly, for patients with an inadequate response to first-line hormone therapy, which will be half of them, initiate a structured conversation about GNRH antagonists, escalating therapy to something more effective.
- 44:09SPEAKER_00: Include some counseling about potential side effects, add back therapy, and how that can alleviate the side effects, what type of monitoring we might want to do, and realistic expectations for timed response.
- 44:23SPEAKER_00: If they're not responding to a GNRH antagonist, again, they can be referred to somebody who has expertise in endometriosis or when their symptoms are truly refractory to adequate medical management.
- 44:35SPEAKER_00: Maybe then it's time to think about surgery and move on to a surgical specialist, but that should be our last course of action.
- 44:43SPEAKER_00: Medical therapy initially uh is appropriate.
- 44:48SPEAKER_00: At every visit with your endometriosis uh patient, ask at least one structured SDM question addressing symptom priority, fertility goals, and treatment preferences.
- 45:03SPEAKER_00: Again, we want to work with our patients.
- 45:05SPEAKER_00: This should be shared decision making where we address their priorities uh in um deciding which treatment options are best to them.
- 45:15SPEAKER_00: And when initiating new endometriosis treatment regimens, provide a brief written follow-up plan that reminds them of that reassessment interval to get them back to see if it's working, that we have second-line therapies available and what our criteria are for escalation.
- 45:34SPEAKER_00: For me, six to eight weeks, if they're not better, if their pain is not resolved, I talk to them about a plan to escalate and also let them know how best to schedule that appointment or contact the office if there are side effects or uh to address escalation.
- 45:52SPEAKER_01: Thank you to our audience for joining us, and thank you to CME Outfitters for the opportunity to participate in this important conversation.
- 46:00SPEAKER_01: Thank you again for joining us today.